Home ProductsTren Anabolic Steroid

Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5

Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5

    • Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5
    • Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5
  • Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5

    Product Details:

    Place of Origin: China
    Brand Name: RAWSGEAR
    Certification: ISO 9001, USP, GMP
    Model Number: 5630-53-5

    Payment & Shipping Terms:

    Minimum Order Quantity: 10g
    Price: negotiation
    Packaging Details: Discreet ways of packing for Customs pass guaranteed
    Delivery Time: 3-5 work days
    Payment Terms: T/T, Western Union, MoneyGram, Bitcoin
    Supply Ability: 1000kg/month
    Contact Now
    Detailed Product Description
    Product Name: Tibolone CAS: 5630-53-5
    Purity: 99% Appearance: White Powder
    MF: C21H28O2 MW: 312.45

    Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5


    Quick Detail:

    Product Name Tibolone
    Alias LIVIELLA; LIVIAL
    CAS Registry Number 5630-53-5
    Einecs No 227-069-1
    Molecular Formula C21H28O2
    Molecular Weight 312.45
    Purity 99.0%
    Grade Pharmaceutical Grade
    Appearance White powder
    Melting point 169 °C
    Boiling point 447.4±45.0 °C(Predicted)
    Density 1.13±0.1 g/cm3(Predicted)

     

    What is tibolone?

    Tibolone is a synthetic steroid molecule which is, in essence, a progestogen. Post absorption, its metabolites have oestrogenic, progestogenic and androgenic properties. The oestrogenic effects are exerted mainly in brain, bone and vaginal tissues and are responsible for control of vasomotor symptoms and prevention of bone loss. The effect of the progestogenic metabolites on the endometrium prevents hyperplasia. Limited conversion of oestrone to oestradiol may reduce the oestrogenic effects of tibolone in the breast. Androgenic effects are thought to enhance testosterone availability by reducing sex hormone binding globulin (SHBG).

    How effective is tibolone?

    In randomized trials tibolone 2.5mg has been found to be more effective than placebo and less effective than standard dose combined MHT in controlling vasomotor symptoms. Moderate-quality evidence also suggests that tibolone is associated with a higher rate of unscheduled bleeding than placebo, but a lower rate of bleeding than with combined MHT.

     

    Tibolone has been found to be effective in the prevention of bone loss. The effect of tibolone on bone seems similar to MHT. In the LIFT study the absolute reduction in vertebral fractures in the tibolone group, was 8.6 (95% CI, 4.4 to 12.9) per 1000 person-years with a relative reduction hazard of 45% (95% CI, 26 to 59). There was also a reduction in the absolute risk of nonvertebral fracture. Adverse events seen in the LIFT study limit its usefulness for the older population with low bone density.

     

    Tibolone decreases SHBG and increases bioavailable testosterone. In addition, the Δ4-isomer of tibolone stimulates androgen receptors. Both of these actions are thought to have a positive effect on sexual function. However, there is low quality evidence for this. A Cochrane meta-analysis of studies of tibolone v placebo in postmenopausal women found no effect to a small benefit, with wide confidence intervals.

     

    Randomized controlled trials have studied tibolone v MHT for sexual function. Two large trials have studied tibolone v transdermal MHT. The LISA study randomised 403 women to tibolone or transdermal oestradiol/norethisterone for 24 weeks. Both treatments found improvement in the satisfying sexual event rate for both groups, with no difference between groups. In the per protocol analysis, but not in the intent-to-treat analysis, the increase in Female Sexual Function Index (FSFI) scores was significantly greater in the tibolone group when compared with the MHT group (p = 0.025). A 48-week study of 437 women randomized to tibolone or transdermal oestradiol/norethisterone found improvement in both groups on McCoy’s Sex Scale Questionnaire.

     

    Other studies compared tibolone with oral MHT. A study comparing tibolone, oral CEE/MPA and placebo found a significant increase in sexual function, as measured by the FSFI, in the tibolone group but no statistically significant difference between tibolone and CEE/MPA. Uygur et al found improved sexual function in tibolone v CEE/MPA in face-to-face questioning rather than a standardised questionnaire.

    Who can use tibolone?

    Tibolone can be used by women who have an intact uterus and have not experienced a natural period for at least one year. If taken sooner, irregular bleeding may be experienced. Women can also transition from cyclical, or combined continuous MHT onto Tibolone. Tibolone has the same contraindications as any oral combined MHT.

    Side-effects of tibolone

    Side-effects may include headache, dizziness, nausea, abdominal pain, swollen feet and itching. Breast tenderness is uncommon. Slight bleeding or spotting may commonly occur initially but tends to subside after a few months. Amenorrhoea is achieved by about 80% of women after the first month of treatment with tibolone and over 90% after the third month of therapy.

     

    Safety of tibolone:

     

    In the LIFT study of tibolone for the prevention of bone loss and osteoporotic fractures, there was an increase in stroke in the tibolone group compared with the placebo group. This was mainly seen in women over 60 years of age. The increase among women in their 50s was 4 extra cases per 1000 and among women in their 60s, an extra 13 cases per 1000 women.
    Tibolone decreases total and LDL cholesterol and triglyceride levels. However, it also decreases HDL cholesterol. The impact of these changes on cardiovascular events is not clear. Meta-analysis of only four studies examining this showed a non-significant odds ratio for cardiovascular events with tibolone of 1.38 [ 0.84, 2.27 ].


    The data on breast safety have been contradictory. Preclinical data on tibolone concentrated on its effect on oestrogen metabolism in the breast. Tibolone and its metabolites reduce sulfatase and stimulate sulfotransferase activity thereby inhibiting the formation of active
    oestrogenic substances and promoting the formation of inactive oestrogens . It is associated with less breast density than conventional continuous combined MHT. It was therefore thought to be safer, in terms of breast cancer risk, for women at risk of breast cancer or even those who had had breast cancer.

     

    Bodybuidling Steroid Hormone Tibolone For Treatment of Menopausal Syndrome 5630-53-5

     

    Our Advantage:


    1, High quality with competitive price:
    1)Standard: Enterprise Standard
    2)All Purity≥99%
    3)We are manufacturer and can provide high quality products with factory price.

    2, Fast and safe delivery
    1)Parcel can be sent out in 24 hours after payment. Tracking number available
    2)Secure and discreet shipment. Various transportation methods for your choice.
    3)Customs pass rate ≥99%
    4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.

    3, We have clients throughout the world.
    1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
    2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
    3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.

    Contact Details
    RAWSGEAR MANUFACTURER

    Contact Person: Gayle

    Tel: +8613264734726

    Send your inquiry directly to us (0 / 3000)